Figure 7. The ROC curves and nomogram about FHL2 and overall survival in lung cancer. (A) ROC curves evaluating the value of FHL2 for predicting overall survival in lung cancer patients. (B) Nomogram predicted 1-year overall survival versus actual 1-year overall survival. (C) Nomogram predicted 3-year overall survival versus actual 3-year overall survival. (D) Nomogram predicted 5-year overall survival versus actual 5-year overall survival. (E–G) Decision curve analysis reflects the feasibility of FHL2 in predicting 1-year, 3-year, and 5-year overall survival of patients.